Allarta Life Science
Allarta Life Science is a pre-clinical stage life science company, with a proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia. Allarta is raising a Pre-Series A Bridge financing to support pre-clinical studies (diabetes), determining path to Orphan Drug cell models for small and large animal studies, and R&D investment on pipeline IP and core technologies within the company.
Presenter: Harald Stover, Co-Founder & CEO
Read More
ChipCare
ChipCare is a pre-revenue biotech company based in Toronto. We are in late stage development of a novel point-of-care in-vitro diagnostic platform for the differential diagnosis of infectious diseases and health monitoring. The platform includes an analyzer and single use cartridges which contain test specific reagents. The platform is intended for use in community clinics, congregate care residences, chain pharmacies, under-serviced communities etc. and provides a test result in ~ 30 minutes. This enables health care workers to provide diagnosis and treatment in a single visit, minimizing the spread of disease and delays in treatment. We expect to go to market with our initial STI assay in mid-2022.
Presenter: Jeffrey Weisberg, Chief Executive Officer and President
Read More
Elarex
Elarex is commercializing its proprietary PT120 formulation technology, proven to stabilize vaccines and biotherapeutics so that cold chain distribution is no longer required. We recently secured $500k in pre-seed financing (another $400k pending) and were awarded NSERC I2I Grant. Our technical team is assembled and we have three paid pilots ongoing with top tier vaccine manufacturer. Business Development leader added to team. We are seeking $4,000,000 to aggressively pursue mRNA/LNP opportunity,expand leadership and technical team, enhance IP portfolio, and expand number of partners and projects.
Presenter: Robert DeWitte, Co-Founder and CEO
Read More
Innovakine
Using cutting-edge protein and cell engineering approaches, Innovakine has developed a proprietary platform technology that allows clinicians to send exclusive, customized signals to immune cells and other cell types anywhere in the body, with broad clinical applications in the fields of cancer immunotherapy, infectious disease, autoimmunity, transplantation and regenerative medicine. Innovakine was founded in 2019 by Brad Nelson PhD (Distinguished Scientist, British Columbia Cancer; Professor, UBC) and Martin Boulanger PhD (Professor, University of Victoria) following a successful research collaboration with Zymeworks Inc., a clinical-stage biotechnology company. Innovakine is raising $4M in seed funding to complete pre-clinical POC studies in murine solid tumor models.
Presenter: Brad Nelson, Co-founder and CEO
Read More
IntelliStem
IntelliStem is an early stage biotech company that has created the next generation of cell therapy products to target catastrophic diseases such as cancer and Infectious diseases. Its first product “Super Sentinel CellsTM” is an off-the-shelf product to target cancer that has shown an 80% success rate compared to 20% of incumbents In-vivo, which can target both blood and solid tumors offering scalable and more efficacious solutions, at a fraction of the cost of the current platforms. We hope to use investor funds to advance our assets to market through clinical trials, then out-licensing and co-development.
Presenter: Riam Shammaa, Chief Executive Officer and Co-Founder
Read More
JN Nova Pharma Inc.
JN Nova Pharma Inc’s lead therapeutic molecule, JN2019, is a potent corona viral neutralizing agent, acting via an enhanced ACE2 decoy, which inhibits viral entry and is immunologically conjugated to cause viral clearance. By simultaneously replacing the lost ACE2 function, it potentially will counteract the deleterious effects of acute respiratory disease syndrome (ARDS) and reduce pathogenic innate immune activation and inflammation caused by the virus.
Presenter: John Gillard, CEO
Read More
Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
Orion Biotechnology Canada
Orion Biotechnology is a clinical stage biotechnology company developing GPCR-targeted therapeutics for the treatment of cancer and other serious diseases. This novel scientific approach is enabled by Orion’s proprietary high-throughput drug discovery platform. Our disruptive analog-based technologies position OB to become a premier GPCR-focused company to deliver next generation therapeutics not only for Orion’s pipeline, but also in collaboration with other biopharmaceutical companies. We plan to advance our lead candidate into Phase 1b/2a trial in Oncology and complete lead optimization of 2 additional drug candidates.
Presenter: Antaole Klepatskyi, COO
Read More
PlantForm Corporation
PlantForm is a biotechnology company headquartered in Guelph, Ontario, Canada, with a proven technology used to develop and manufacture high value proteins and antibodies as diagnostics, drugs, and vaccines. PlantForm’s patented vivoXPRESS® technology uses genetically modified tobacco plants to manufacture very low-cost products using fully contained vertical growth environments. The company is revenue generating from contracts including production of components for COVID-19 diagnostic kits. The proceeds of the financing will advance company's lead medical countermeasure drug through IND enabling and Phase 1 Clinical Studies to enter the market in 2-3 years, no Phase 2 or 3 Clinical trials being required.
Presenter: Don Stewart, CEO
Read More
Providence Therapeutics
Providence Therapeutics has successfully raised over $10.7 million over the last year to support its personalized cancer vaccine program, using it mRNA vaccine technology. Since the COVID-19 pandemic, we have redeployed our GMP production capacity to develop and manufacture a made-in-Canada COVID-19 mRNA vaccine. We have clinical trials planned for early 2021 that are supported by the NRC. Scale-up of our vaccine is currently underway and is supported by $3.5 million in contributions from the NGen supercluster. The proceeds from our series B will support continued Phase 2 clinical trials and scaled production to support commercialization.
Presenter: Brad Sorenson, CEO
Read More
Synmedix
Synmedix is a newly-founded biotechnology company created to commercialize a novel platform that dramatically enhances the effectiveness of antibiotics to address unmet medical need posed by the global health crisis in antibiotic resistance. Synmedix was founded on McMaster University technology, showing that bicarbonate dramatically improves the efficacy and spectrum of several antibiotics enabling the treatment of multidrug-resistant infections. Synmedix is seeking seed funding for preclinical studies leading to an Investigational New Drug (IND) for its lead product BCX-4, azithromycin plus bicarbonate, for a first-in-class treatment of diabetic foot ulcer infections. Clinical development will leverage the FDA’s accelerated 505(b)(2) pathway.
Presenter: Eric Brown, CEO
Read More
TATUM Bioscience
TATUM Bioscience is a synthetic biology startup developing a new class of drug called synthetic live biotherapeutics (synLBT). synLBT are probiotics engineered to execute advanced therapeutic tasks. This technology disrupts the conventional drug development process by allowing us to build drugs instead of discovering them. Using its unique modular platform, TATUM design synLBTs to tackle diseases for which conventional drugs have now reached their limits and focuses its efforts on antibiotic resistance and oncology. The company will open a seed round in Q4 of 2021 to advance its programs, expand its IP portfolio, and conduct INTERACT and pre-IND meetings.
Presenter: Jean-François Millau, CEO
Read More
Virica
At Virica, we believe that viral medicines hold the key to unlocking the future of human healthcare. However, there are unmet needs in the field of viral therapeutics that limit their development and scalability. Virica fills this void through our proprietary viral sensitizer or VSE technology, in order to realize the promise of viral medicines to extend the horizons of human healthcare. We deploy and monetize our versatile VSE small molecules by working with vaccine and gene therapy manufacturers to reduce their cost of goods, and by developing a pipeline of enhanced viral therapeutics for cancer and other diseases.
Presenter: Jean-Simon Diallo, Scientific Founder/CEO
Read More
